Parkinson's

The primary pathology in parkinson's disease (PD) is the loss of dopaminergic neurons in the substantia nigra pars compacta, leading to a decrease in dopamine levels in the striatum. The decrease in dopaminergic input into the striatum primarily affects movement but can also cause cognitive and psychiatric symptoms. MuriPhys offers a precise and reproducible intraparenchymal (IPa) drug product delivery into the substantia nigra, as well as other delivery methods such as intracerebroventricular (ICV), intrathecal (IT) and intra cisterna magna (ICM) that allow broader spread of drug products in the CNS. By utilizing state-of-the-art stereotaxic robots, we can deliver test articles directly to subcortical structures with a 1 µm accuracy.

To complement our CNS delivery, we offer behavioral tests and in vivo electrophysiology that encompass all aspects of the disease, including (but not limited):